Synthetic ACTH

Drug Overview

In the specialized field of Endocrinology, precision is the cornerstone of effective treatment. Before a patient can begin Hormone Replacement Therapy or long-term metabolic management, a definitive diagnosis must be established. Synthetic ACTH, known by the generic name Cosyntropin, serves as the gold-standard tool in this diagnostic process. It belongs to the Diagnostic Agent drug class and is essential for evaluating the integrity of the adrenal glands.

Unlike therapeutic hormones designed for daily use, this agent is utilized specifically to “stress-test” the body’s ability to produce cortisol. By mimicking the signals sent from the brain to the adrenal glands, it allows medical practitioners to differentiate between various types of adrenal insufficiency and other metabolic imbalances.

• Generic Name: Cosyntropin
• Active Ingredient: Synthetic ACTH (Adrenocorticotropic Hormone)
• US Brand Names: Cortrosyn
• Drug Class: Diagnostic Agent (Pituitary Hormone Analog)
• Route of Administration: Intravenous (IV) injection or Intramuscular (IM) injection
• FDA Approval Status: Fully FDA-approved as a diagnostic screening agent for adrenal cortical insufficiency.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Synthetic ACTH works, we must first look at the natural Hypothalamic-Pituitary-Adrenal (HPA) Axis. In a healthy body, the pituitary gland releases natural ACTH, which travels through the bloodstream to the adrenal glands (located atop the kidneys). There, it signals the adrenal cortex to produce and release cortisol, the body’s primary stress hormone, which regulates blood pressure, blood sugar, and immune response.

Cosyntropin is a synthetic polypeptide that contains the first 24 amino acids of the natural human ACTH molecule. This specific sequence is responsible for the full biological activity of the hormone. At the molecular level, its mechanism of action involves:

1. Receptor Binding: Upon injection, the drug binds to the Melanocortin 2 Receptors (MC2R) on the surface of the cells within the adrenal cortex.
2. Cellular Signaling: This binding activates an enzyme called adenylate cyclase, which increases the levels of cyclic AMP (cAMP) within the adrenal cells.
3. Steroidogenesis Stimulation: The increase in cAMP triggers a cascade of enzymatic reactions that convert cholesterol into pregnenolone, the precursor to all adrenal steroids.
4. Cortisol Release: This culminates in the rapid synthesis and secretion of cortisol into the bloodstream.

In a diagnostic setting, the practitioner measures blood cortisol levels before and roughly 30 to 60 minutes after the injection. A “normal” adrenal gland will respond to this Targeted Therapy stimulus by significantly increasing its cortisol output. If the adrenal glands are damaged or exhausted (Primary Adrenal Insufficiency), they will fail to respond, even though the synthetic signal is present.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved use of Cosyntropin is as a diagnostic screening agent in patients suspected of having adrenal cortical insufficiency (Addison’s Disease). It is the central component of the “ACTH Stimulation Test.”

Other Approved & Off-Label Uses

While its primary role is diagnostic, it is occasionally used in specialized contexts or research protocols to evaluate adrenal response in complex metabolic states.

• Primary Adrenal Insufficiency (Addison’s Disease): To confirm permanent adrenal damage.
• Secondary Adrenal Insufficiency: To evaluate if the adrenal glands have “atrophied” due to a lack of natural signal from the pituitary gland.
• Congenital Adrenal Hyperplasia (CAH): Occasionally used off-label to stimulate the production of adrenal precursors (like 17-hydroxyprogesterone) to aid in diagnosing specific enzyme deficiencies.
• Post-Corticosteroid Evaluation: To determine if a patient’s HPA axis has recovered after stopping long-term Hormone Replacement Therapy or high-dose steroid treatment.

Primary Endocrinology Indications:

• HPA Axis Screening: Determining if the communication between the brain and the adrenal glands is intact.
• Differential Diagnosis: Distinguishing between primary adrenal failure (the gland itself is broken) and secondary failure (the brain isn’t sending the signal).

Dosage and Administration Protocols

Because Synthetic ACTH is a diagnostic agent and not a maintenance drug, it does not involve a titration schedule. Accuracy in timing the blood draws is the most critical factor for a valid result.

Administration Timing:

The test is ideally performed in the morning (between 7:00 AM and 9:00 AM) to align with the body’s natural circadian rhythm of cortisol production. Baseline blood is drawn, the dose is administered (IV or IM), and subsequent blood samples are typically drawn at 30 minutes and 60 minutes post-injection.

Adjustments and Warnings:

• Renal/Hepatic Insufficiency: Generally, no dose adjustment is required for kidney or liver impairment as the drug is used only once for diagnosis.
• Pregnancy: Should be used only if clearly needed.
• Differentiating Formulations: Cosyntropin is a rapid-acting agent. It is distinct from long-acting, gel-based ACTH formulations used for certain therapeutic treatments.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical research spanning the 2020-2026 period confirms that the 0.25 mg dose of Cosyntropin provides a maximal stimulus to the adrenal cortex, ensuring that any lack of response is due to adrenal failure rather than an insufficient dose.

Biochemical Targets

In diagnostic trials, the “biochemical target” is a post-stimulation serum cortisol level. While specific lab standards vary, the general consensus for a “normal” response is a peak cortisol level exceeding 18 to 20 micrograms per deciliter (mcg/dL).

• Mean Response: In healthy individuals, cortisol levels typically double from baseline within 60 minutes.
• Efficacy in Addison’s Disease: Clinical data shows 100% sensitivity in detecting primary adrenal insufficiency. Because the adrenals are physically damaged, they show near-zero response to the synthetic stimulus.

Recent Research Trends

Studies between 2022 and 2025 have explored the “Low-Dose ACTH Test” (using 1 microgram instead of 250 micrograms). Research suggests the low-dose test may be more sensitive for detecting “partial” secondary adrenal insufficiency, as the standard 250 mcg dose might be powerful enough to force a response from even a partially atrophied gland.

Safety Profile and Side Effects

Black Box Warning:

There is no “Black Box Warning” for Cosyntropin. It is generally considered highly safe due to its single-use nature and rapid clearance from the body.

Common Side Effects (<10%)

Because this is a single-use diagnostic, side effects are rare and usually transient.

• Injection Site Reaction: Redness or swelling at the IV or IM site.
• Skin Flushing: A brief feeling of warmth or redness in the face.
• Nausea: Mild, short-lived upset stomach.

Serious Adverse Events

• Anaphylaxis: Rare but serious allergic reactions. Patients with a history of hypersensitivity to natural ACTH are at higher risk.
• Adrenal Crisis (Theoretical): While the drug itself stimulates the adrenals, the process of testing (withholding maintenance steroids before the test) can lead to an adrenal crisis in severely deficient patients.
• Electrolyte Shifts: Minimal, though extremely rare instances of transient potassium or sodium shifts have been noted in research.

Management Strategies: Practitioners must have emergency supplies (including IV fluids and hydrocortisone) available if the patient shows signs of an adrenal crisis during the testing period.

Research Areas

Direct Clinical Connections

Active research (2024-2026) is investigating the drug’s interaction with the HPA axis in patients suffering from “Long-COVID” and chronic fatigue syndromes. Researchers are using Synthetic ACTH to determine if these patients have a subtle “blunting” of adrenal response that might explain persistent fatigue.

Generalization & Advancements

The development of Biosimilars for Cosyntropin is currently a focus for international pharmaceutical brands to increase global accessibility and reduce diagnostic costs. Additionally, there is research into Novel Delivery Systems, such as nasal spray ACTH analogs, which would eliminate the need for injections during screening.

Severe Disease & Prevention

By providing a definitive diagnosis of adrenal insufficiency, Cosyntropin is the primary tool for preventing the long-term macrovascular and microvascular complications of untreated Addison’s disease, such as chronic hypotension (low blood pressure) and life-threatening adrenal crises during surgery or severe illness.

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before the test, the Endocrinologist must establish a baseline.

• Baseline Diagnostics: Morning (8:00 AM) serum cortisol and natural ACTH levels.
• Medication Review: Patients must often withhold oral glucocorticoids (like prednisone or hydrocortisone) for 12 to 24 hours prior to the test to prevent interference with results. Estrogen-containing birth control may also need to be noted, as it can artificially raise measured cortisol levels.
• Specialized Testing: Electrolyte panels (Sodium and Potassium) are often checked concurrently.

Monitoring and Precautions

• Vigilance: During the 60-minute test period, the patient should be monitored for signs of dizziness or nausea.
• Lifestyle: No specific Medical Nutrition Therapy (MNT) is required for the test, though fasting is often preferred for more accurate results.

“Do’s and Don’ts” list

• DO inform your doctor if you have had an allergic reaction to ACTH in the past.
• DO ensure the lab draws your blood at the exact 30-minute and 60-minute marks.
• DO resume your normal medications immediately after the test unless told otherwise.
• DON’T perform the test during a period of acute, unrelated illness (like the flu), as this can skew the results.
• DON’T stop your maintenance steroids for the test without a specific “rescue plan” from your doctor.

Legal Disclaimer

This document is for informational purposes only and does not constitute medical advice. The “ACTH Stimulation Test” must be performed under the supervision of a qualified medical professional. Always consult with your Endocrinologist regarding the interpretation of diagnostic results and before making any changes to your medication or treatment plan. The information provided reflects clinical knowledge as of 2026.